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0929-6646/Copyright ª 2015, ElsevierHepatitis B virus (HBV) infection is endemic in Taiwan. After the implementation of universal
hepatitis B vaccination, there was a significant reduction of hepatitis B surface antigen (HBsAg)
seropositivity and HBV-related hepatocellular carcinoma (HCC) incidence in children, teen-
agers, and young adults. However, the incidence of HBV-related HCC in adults remains high.
Through several community- and hospital-based cohort studies, the viral factors affecting
the prognosis of HBV carriers have been illustrated. Serum HBV DNA level > 2000 IU/mL at
study entry starts to increase the risks of cirrhosis and HCC in adult patients with chronic
HBV infection. In addition, serum HBsAg level > 1000 IU/mL is associated with a higher risk
of HCC in HBeAg-negative patients with low viral load. Virologically, HBV genotype C/D and
core promote/pre-S mutations correlate with an increased HCC risk. Recently, a risk calculator
has been developed to predict HCC in noncirrhotic patients with external validation. Thera-
peutically, hospital-based cohort and population-based nationwide studies indicated that
interferon and nucleos(t)ide analogue treatments could reduce the incidence of HCC over
time. Towards the ultimate goal of HBV eradication, several novel agents aiming at viral and
host targets are under development. In addition, the immune therapy may play a key role in
HBV cure in the foreseeable future.
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Hepatitis B virus (HBV) is one of the most common viral
infections in humans. Global prevalence of chronic HBV
infection is heterogeneous, with 2e20% of a given popula-
tion being infected with HBV.1 Persistent HBV infection has
a wide disease spectrum, including inactive carrier state,
chronic hepatitis, liver cirrhosis, and hepatocellular carci-
noma (HCC).1 The lifetime risk of patients with chronic HBV
infection to develop cirrhosis, liver failure, or HCC is esti-
mated to be as high as 15e40%.2 Through previous in-
vestigations on the molecular epidemiology of HBV, several
hepatitis B viral biomarkers, including HBV viral load,
quantitative hepatitis B surface antigen (HBsAg), and HBV
genotype are known to affect the long term outcomes of
patients with chronic HBV infection.3,4 The impact of hep-
atitis B viral biomarkers on the natural course of patients
with chronic HBV infection has been explored in both
community- and hospital-based cohort studies.5 In addi-
tion, recent advances in anti-HBV treatment have docu-
mented the prevention of disease progression and
reduction of HCC risk in patients with chronic HBV infec-
tion. In this review, the predictive roles of hepatitis B viral
biomarkers on the clinical outcomes and challenges of anti-
HBV therapy in Taiwan will be summarized and discussed.Changing burden of HBV infection and HBV-
related HCC after HBV vaccination in Taiwan
HBV infection is endemic in Taiwan and most patients with
chronic HBV infection acquire the virus early in life.6 Before
the launch of the universal hepatitis B vaccination in 1984,
the prevalence of HBsAg in the general population of
Taiwan was approximately 11e20%, which was the highest
in the world.7,8 After the implementation of universal
hepatitis B vaccination, the HBsAg seropositive rate in
children decreased dramatically from 11% to 0.9% in 2012.9
Of particular note, the incidence of HCC in children also
decreased from 0.52 per 100,000 children in those born
before universal vaccination program to 0.13 per 100,000 in
those born afterwards.10 However, a recent analysis to
determine the total and changing burden of chronic HBV
infection and to evaluate the serological status between
vaccinated and unvaccinated individuals in Taiwan was
performed with participants of “The Taiwanese Survey on
Prevalence of Hyperglycemia, Hyperlipidemia and Hyper-
tension” in 2002 (n Z 6602), and 4088 participants had
follow-up surveys in 2007. The results showed that the
overall prevalence of chronic HBV infection was 13.7% and
two thirds had past exposure (antibody to hepatitis B core
antigen; anti-HBc, 68.46%) in 2002. The vaccinated cohort
tended to have lower prevalence of HBsAg and anti-HBc,
and higher proportion of anti-HBs and HBeAg positivity,
genotype C and high viral load. In the vaccinated cohort,
none acquired new exposure and became HBsAg positive,
demonstrating the durability of vaccination through
teenage and young adulthood. This comprehensive,
population-representative survey indicated that 20 years
after universal vaccination, the backlog still composed a
substantial burden of chronic HBV infections in Taiwan.11The etiological association between persistent HBV
infection and HCC has been well documented, including the
geographical correlation between the prevalence of HBsAg
and the incidence of HCC, the high prevalence of HBsAg in
HCC patients, the increased relative risk of HCC in HBsAg
carriers, the presence of integrated HBV DNA in HCC tissue,
and the association of chronic hepadnavirus infection with
HCC in animal models.1,12 The reduction of childhood HCC
incidence after universal HBV vaccination in Taiwan and
other countries further lends support to the fact that HBV-
related HCC can be primarily prevented by HBV vaccination
and it is thus the first cancer preventive vaccine.13
Despite effective immunoprophylaxis to interrupt
mother-to-infant HBV transmission in our clinical practice,
mothers positive for HBeAg with a high viral load are the
major causes of immunoprophylactic failure. The estimated
predictive rates of mother-to-infant transmission at
maternal viral load levels of 5e9 log10 copies/ml were 0.9%,
2.6% 6.6%, 14.6%, and 27.7%, respectively.14 To further
reduce mother-to-infant HBV transmission, a prospective,
multicenter trial enrolling 118 HBeAg-positive pregnant
women with HBV DNA  7.5 log10 IU/mL was conducted in
Taiwan. The mothers received no medication or 300 mg
tenofovir disoproxil fumarate (TDF) daily from weeks 30e32
of gestation until 1 month postpartum. The encouraging
data showed that maternal TDF treatment could decrease
infant HBV DNA level at birth, infant HBsAg positivity at 6
months, and ameliorate maternal alanine transaminase
(ALT) elevations postpartum.15
Nevertheless, the annual incidence of HCC in the un-
vaccinated adult Taiwanese population remains high,
ranging from 15/100,000 in the 1980s to approximately 30/
100,000 in the 2000s.16 Among these unvaccinated people,
a large proportion of patients with chronic HBV infection
are still at risk of developing cirrhosis and HCC if left un-
treated. Therefore, administration of effective antiviral
agents to those in need, to slow disease progression is of
paramount importance in clinical practice.
Factors associated with long term outcomes
from HBV cohort studies in Taiwan
Hepatitis B viral load and quantitative HBsAg in
predicting HCC risk
With results from several large cohort studies in Taiwan,
the hepatitis B viral factors affecting the prognosis of pa-
tients with chronic HBV infection have been unveiled (Table
1).17e19 The impact of baseline serum HBV DNA level on
cirrhosis and HCC development in adult patients with
chronic HBV infection was first assessed in the Risk Evalu-
ation of Viral Load Elevation and Associated Liver Disease/
Cancer-Hepatitis B Virus (REVEAL-HBV) study.17,20 Among
3653 adult Taiwanese patients with chronic HBV infection
over a mean follow-up period of 11.4 years, the cumulative
incidence of HCC increased with serum HBV DNA levels in a
dose dependent manner. The incidence increased from
1.3% to 14.9% in patients with an HBV DNA level of < 300
copies/mL (w60 IU/mL) and  106 copies/mL
(w200,000 IU/mL), respectively (p < 0.001). The relative
risk began to increase at an entry HBV DNA level of 2000 IU/
Table 1 Summary of landmark hepatitis B virus cohort studies from Taiwan.
Cohort REVEAL-HBV ERADICATE-B C-TEAM REACH-B
Study design Community-based cohort Hospital-based cohort Hospital-based cohort International
collaboration
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Main results Baseline serum HBV DNA
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In HBeAg-negative
patients with an HBV
DNA level < 2000 IU/mL,
an HBsAg







reduction of HCC risk
(adjusted hazard ratio:
0.40, 95% CI: 0.27e0.60)
in cirrhosis patients
A 17-point risk score of
HCC, including 5
predictors (sex, age,
serum ALT level, HBeAg
status, & serum HBV DNA
levels) was developed.
The risk score precisely
estimated the risk of
developing HCC at 3 y,
5 y, & 10 y of follow-up.
Control of HBV infection in Taiwan 903mL (hazard ratio; HR: 2.3; 95% confidence interval; CI:
1.1e4.9; p Z 0.02). Patients with HBV DNA levels of 
200,000 IU/mL had the greatest risk (HR: 6.1; 95% CI:
2.9e12.1; p < 0.001). In particular, the dose-dependent
relationship was most marked in HBeAg seronegative pa-
tients with normal serum ALT levels and no cirrhosis at
study entry.17,21 In summary, the REVEAL-HBV cohort study
revealed that HBV viral load is a strong risk predictor for
HCC development in patients with chronic HBV infection,
regardless of HBeAg status, ALT level, and other known risk
factors.
As quantification of serum HBsAg becomes widely
available, the association between HBsAg level and HCC
was first addressed by the Elucidation of Risk fActors for
DIsease Control or Advancement in Taiwanese Hepatitis B
Carriers (ERADICATE-B) hospital-based cohort study.19
Similar to the findings derived from the REVEAL-HBV com-
munity-based cohort study, both elevated HBV DNA and
HBsAg levels were positively associated with HCC develop-
ment in a doseeresponse manner in patients with HBV DNA
levels > 2000 IU/mL. Particularly, among 1068 HBeAg-
negative patients with HBV DNA levels < 2000 IU/mL, the
HCC risk significantly increased in those with HBsAg level 
1000 IU/mL compared with those with HBsAg level <
1000 IU/mL (HR:5.4; 95% CI:2.1e14.2). Multivariate analysis
revealed that a HBsAg level  1000 IU/mL was an inde-
pendent risk factor for HCC development (HR:13.7; 95%
CI:4.8e39.3). Furthermore, the relationship of HCC risk
with dynamic changes of serum HBV DNA, HBsAg, and ALT
levels was evaluated in the ERADICATE-B cohort. Compared
to patients with persistently low HBV DNA, HBsAg, or ALT
levels, those with persistently high levels of these three
factors were at a higher risk of HCC over time. The recent
update of the REVEAL-HBV cohort also confirmed that the
HBsAg level was complementary to the HBV DNA level in
stratifying HCC risks, especially in patients with HBV DNAlevel < 200,000 IU/mL.22 Taken together, both cohorts
firmly suggest the promising predictive role of HBsAg in HBV
patients with low viral load.
HBV genotype/variants and risk of cirrhosis/HCC
At least 10 HBV genotypes (AeJ) have been defined viro-
logically, and HBV genotype has been documented to have
specific geographic distribution and impact on the long
term outcomes of HBV infection.23 Two community based
prospective cohort studies of Taiwanese patients with
chronic HBV infection demonstrated that HBV genotype C
was associated with an increased risk of cirrhosis/HCC
compared to genotype B. For example, genotype C-infec-
ted patients who also had a very high viral load had a 26-
fold higher risk of HCC than those with other genotypes
and low or undetectable viral loads.24,25 The ERADICATE-B
cohort study also showed genotype C patients had a
higher annual incidence rate of HCC than genotype B pa-
tients by univariate analysis.19 These findings confirmed
that genotype C correlates with a higher risk of HCC
development than genotype B.
Of naturally occurring HBV mutants, several mutations in
the X gene of the HBV genome are frequently found in
patients with HBV-related HCC.26e29 The 3ʹ-end of the X
gene is frequently deleted in HCC cells, leading to a C-
terminal truncated HBx protein, and may contribute to
hepatocarcinogenesis via the activation of cell proliferation
and loss of proapoptotic ability.29e31 Several cross-sectional
studies revealed that dual mutations in basal core promoter
(BCP) A1762T/G1764A were strongly associated with the
risk of HCC development.32e36 The REVEAL-HBV cohort
study further confirmed BCP A1762T/G1764A mutations as
an independent predictor for HCC development (HR:1.73;
95% CI:1.13e2.67; p Z 0.013).24 A subgroup analysis from
the ERADICATE-B cohort showed that a higher proportion of
904 C.-L. Lin, J.-H. KaoBCP mutations increased the risk of cirrhosis development
in HBV patients with genotype B or C infection.37 For
example, the risk of cirrhosis was higher in patients with
BCP mutations  45% compared to < 45% in the longitudinal
cohort.
Previous reports also showed that the deletion muta-
tions within the pre-S gene were significantly associated
with the development of cirrhosis and HCC.38e40 HBV pre-S
deletion mutations may lead to defective immunity against
HBV and contribute directly to progressive liver cell damage
and ultimately hepatocarcinogenesis.41Risk calculator for HBV-related HCC in treatment-
naı¨ve chronic hepatitis B patients
Because HCC is the most common cause of mortality in
patients with chronic HBV infection, a simple formula with
different weights for different clinical and virological var-
iables may help clinicians predict the risk of HCC develop-
ment in patients with chronic HBV infection. Based on the
REVEAL-HBV cohort along with international collaboration,
the Risk Estimation for Hepatocellular Carcinoma in Chronic
Hepatitis B study (REACH-B) developed and validated a
predictive score for the risk of development of HBV-related
HCC.42,43 This study included a risk score development
cohort with 3584 noncirrhotic, chronic hepatitis B (CHB)
patients without antiviral treatment (REVEAL-HBV cohort)
and a validation cohort with 1050 patients from three in-
dependent hospitals in Hong Kong and South Korea. The 17-
point risk score included five predictors of HCC, including
sex, age, serum ALT level, HBeAg status, and serum HBV
DNA levels (SALED). The risk score precisely estimated the
risk of developing HCC at 3 years, 5 years, and 10 years of
follow-up in the validation cohort. Additional receiver
operating characteristic (ROC) curves and calibration charts
also confirmed the predictive value of this risk score in
noncirrhotic patients. The areas under an ROC curve
(AUROCs) for predicting 3 year, 5 year, and 10 year HCC risk
were 0.811 (95% CI: 0.790e0.831), 0.796 (95% CI:
0.775e0.816), and 0.769 (95% CI: 0.747e0.790),
respectively.43
Although the REACH-B risk calculator for HCC has been
externally validated in noncirrhotic CHB patients, this
scoring system may underestimate the risk in patients with
low viral load at baseline. Based on the ERADICATE-B
cohort, HBsAg level is known to be a complementary
marker for HCC risk in the low viral load group.19 In the
ERADICATE-B subcohort study, a total of 2165 Taiwanese
HBeAg-negative non-cirrhotic patients were followed for
14.9 years. There was no association between HBsAg level
and HCC in patients with higher viral loads ( 20,000 IU/
mL). HBsAg level was then included to stratify the risk of
HCC in patients with low (< 2000 IU/mL) and intermediate
viral loads (2000e19,999 IU/mL). ROC curve analysis
showed that combining HBV DNA and HBsAg level improved
the prediction of the development of HCC at 10 years
compared to the HBV DNA level alone in patients with low
(< 2000 IU/mL) and intermediate viral loads
(2000e19,999 IU/mL) as well as the overall cohort
(p Z 0.004 and p Z 0.028, respectively).44 In the recent
update of the REVEAL-HBV study, HBsAg level wasincorporated into the HCC risk prediction model.22 Predic-
tive factors of risk included age, sex, family history of HCC,
HBeAg status, serum HBV DNA, ALT, HBsAg levels, and HBV
genotype. The sum risk scores ranged from 0 to 19 in the
HCC prediction model. Patients were categorized by their
sum risk scores into low risk (risk score < 9), medium risk
(risk score 9e12), and high risk (risk score  13) groups. The
observed cumulative risk of HCC for the high risk group was
significantly higher than in the low risk and medium risk
groups (p < 0.001).22 Although the predictive accuracy of
the upgraded REVEAL-HBV risk calculator for HCC was
excellent in noncirrhotic CHB patients, its cost-
effectiveness needs be surveyed.45Impact of antiviral therapy on long-term
outcomes of CHB
Cirrhosis with necroinflammation, deposition of extracel-
lular matrix and shortening of telomeres, leads to cellular
senescence and regeneration nodule. HCC may subse-
quently emerge in the setting of cirrhosis.46 The most
effective tool to prevent the occurrence of HCC in patients
with chronic HBV infection is to receive effective antiviral
agents and halt the disease progression from chronic hep-
atitis to cirrhosis and eventually HCC.47,48 At the time of
writing, seven agents are globally approved for the treat-
ment of CHB, they are standard interferon-a (IFN-a) or
pegylated interferon-a (PEG-IFN-a) and five nucleos(t)ide
analogues (NAs), including lamivudine (LAM), telbivudine
(LdT), entecavir (ETV), adefovir dipivoxil (ADV), and teno-
fovir disoproxil fumarate (TDF).49e52 Previous studies
revealed that long term NA therapy resulted in the
improvement of histologic necroinflammation as well as
reversal of advanced fibrosis or even cirrhosis.53e56 Earlier
randomized control studies showed that IFN and LAM
therapy were protective against HCC development in pa-
tients with chronic HBV infection.57,58 In a meta-analysis
including six eligible studies (3644 patients in total), the
incidence of long term complications (including decom-
pensated cirrhosis, CHB-related death, and HBV-related
HCC) in patients receiving NAs (mainly of LAM and ADV) as
treatment was reduced by 74% (relative risk; RR:0.26, 95%
CI: 0.15e0.47) compared to patients without NA treat-
ment.59 Similarly, another meta-analysis including 11
studies (2122 patients in total) reported that IFN therapy
reduced the risk of cirrhotic complications by 54% (RR:0.46,
95% CI:0.32e0.67, p < 0.001).60 Another meta-analysis also
confirmed that the risk of HCC after IFN and NA (mainly of
LAM and ADV) treatment was reduced by 34% (RR: 0.66, 95%
CI: 0.48e0.89) and 78% (RR: 0.22, 95% CI: 0.10e0.50),
respectively.61 However, there is no large randomized
clinical trial to show a more beneficial effect of NAs with
high potency as well as a high barrier to drug resistance
(ETV and TDF) than earlier generation NAs (LAM and ADV) in
the prevention of HBV-related HCC. A small scale study for
propensity score matching CHB patients with and without
ETV treatment revealed that the cumulative HCC incidence
rates at 5 years were 3.7% and 13.7% for the ETV and control
groups, respectively (p < 0.001). The ETV group were less
likely to develop HCC than those in the control group (HR:































Figure 1 Nucleos(t)ide analogues reduce risk of hepatocel-
lular carcinoma in chronic hepatitis B patients in population-
based and hospital-based cohort studies in Asia. a Nationwide
study: Population-based nationwide cohort study in Taiwan.65
b C-TEAM cohort: Cirrhosis Taiwanese Entecavir Multicenter
study in Taiwan, a hospital-based cohort study.64 c Japan
cohort: A hospital-based cohort study in Japan.62 d Hong Kong
cohort: A hospital-based cohort study in Hong Kong.63
HCC Z hepatocellular carcinoma.
Control of HBV infection in Taiwan 905et al63 reported that cirrhotic patients with ETV treatment
had reduced risks of HCC when compared with historical
untreated patients with cirrhosis (HR:0.55; 95% CI,
0.31e0.99; pZ 0.049). The effect of long term ETV therapy
on the reduction of HCC risk in hepatitis B-related cirrhosis
patients was also investigated in the Cirrhosis Taiwanese
Entecavir Multicenter (C-TEAM) study in Taiwan. In this
large hospital-based cohort study, 503 patients in the con-
trol group and 1123 in the ETV group from 24 academic
centers were enrolled. ETV treatment was associated with
a 60% reduction of HCC risk (adjusted HR: 0.40, 95% CI:
0.27e0.60) in cirrhosis patients.64 The protective effect of
NAs in the development of HCC was further confirmed in a
retrospective, population-based nationwide study in
Taiwan. CHB patients treated with NAs had a significantly
lower 7 year incidence of HCC (7.32%; 95% CI: 6.77%e7.87%)
than patients without NA treatment (22.7%; 95% CI:22.1%e
23.3%; p < 0.001). NA treatment was associated with a
reduced risk of HCC, with an adjusted hazard ratio of 0.37
(95% CI, 0.34e0.39; p < 0.001).65 In addition, the nation-
wide study in Taiwan also revealed that NA treated HCC
patients had a significantly lower HCC recurrence rate after
liver resection (45.6%; 95% CI: 36.5%e54.6% vs. untreated,
54.6%; 95% CI: 52.5%e56.6%; p < 0.001). NA treatment was
independently associated with a reduced risk of HCC
recurrence (HR:0.67; 95% CI: 0.55e0.81; p < 0.001).66
Through long term viral suppression, NA treatment
reduced the risk of HCC development in cirrhotic patients
(Figure 1).62,63,64,65 However, HCC still occurred in some
patients during virological remission.47 A recent systematic
review indicated that current NA therapy consistently
resulted in a significantly lower HCC incidence in Asian
patients with cirrhosis, an overall HCC risk reduction of
30%; in noncirrhotic patients, HCC risk reduction was 80%
overall in some studies. For Caucasian patients, no appro-
priate comparative studies are available to evaluate the
impact of NA treatment on HCC. In addition, achievement
of viral suppression under current NA therapy was associ-
ated with a lower HCC risk in Asians, but not Caucasians.
Studies comparing ETV or TDF with older NAs generally
found no difference in HCC risk reduction between
agents.67 Overall, these data imply that current potent NAs
can reduce HCC but not eliminate it. Thus HCC surveillance
remains mandatory in treated patients, and new treatment
strategies to eradicate intrahepatic HBV cccDNA are ur-
gently required for patients who are at risk of developing
cirrhosis and HCC.Hidden menace: HBV reactivation from
immunosuppression
Acute flares in the natural course of chronic HBV infection
are not unusual. Pathogenesis of acute flares is related to
the interactions between virus and host immune responses
to HBV-encoded antigens.68 Therefore, patients who have
been infected with HBV, including HBsAg-positive carriers
and those with resolved HBV infections with or without
anti-HBs, are vulnerable to increased viral replication and
widespread infection of hepatocytes during immunosup-
pressive therapy or chemotherapy. After discontinuation of
immunosuppressive therapy or chemotherapy, restoredimmune competence will respond to reactive HBV and lead
to hepatitis.69e71 HBV reactivation is well recognized in
patients with malignancies following chemotherapy,72 as
well as in patients with nonmalignant diseases after treat-
ment of immunosuppressive therapy or biologic agents.73,74
The clinical manifestations of HBV reactivation in patients
receiving immunosuppressive therapy or chemotherapy
varies from asymptomatic hepatitis flares to fatal liver
failure. Furthermore, anticancer therapy may be inter-
rupted due to hepatitis flares and affect the prognosis of
cancer. There is ample evidence to support the use of
prophylactic antiviral therapy to avoid HBV reactivation
from immunosuppression.75e79 In the international guide-
lines for the management of HBV infection, prophylaxis
with an antiviral agent before the start of chemotherapy or
immunosuppressive agent is recommended.49e51 However,
patients who have a resolved HBV infection as reflected by
HBsAg negativity with or without anti-HBs and hepatitis B
core antibody positivity also have a risk of HBV reactivation
when host immunity is severely compromised by chemo-
therapy or immunosuppressive agents. In a prospective
study that included 150 lymphoma patients with resolved
HBV infection who received rituximab-based chemo-
therapy, the incidence of HBV reactivation and HBV-related
hepatitis flares was 10.4 per 100 people/y and 6.4 per 100
people/y, respectively. Patients with hepatitis flare
exhibited a significantly higher incidence of reappearance
of HBsAg after HBV reactivation (100% vs. 28.5%;
pZ 0.003).80 The role of antiviral prophylaxis in preventing
HBV reactivation before rituximab-based chemotherapy in
patients with lymphoma with resolved hepatitis B was
elucidated in a randomized controlled trial in Taiwan.81 In
this study, 80 patients with lymphoma and resolved hepa-
titis B undergoing chemotherapy were randomly assigned to
prophylactic ETV therapy or therapeutic ETV at the time of
HBV reactivation. During a mean of 18 months follow-up
period, the ETV prophylactic group had a significantly
1965  Australia antigen 
1984  Universal hepatitis B vaccination for newborns
1997  The incidence of HCC in children decreased
2003  Reimbursement of anti-HBV therapy in Taiwan
2006  REVEAL-HBV cohort study
2011  REACH-B study
906 C.-L. Lin, J.-H. Kaolower rate of HBV reactivation than the control group (2.4%
vs. 17.9%, p Z 0.027). The cumulative HBV reactivation
rates at 6 months, 12 months, and 18 months after
chemotherapy were 8%, 11.2%, and 25.9%, respectively, in
the control group, and 0%, 0%, and 4.3% in the ETV pro-
phylactic group (pZ 0.019).81 Taken together, accumu-
lating evidence strongly recommends that all patients
should be screened for evidence of HBV infection prior to
chemotherapy or immunosuppressive treatment. The pro-
phylactic use of NAs can effectively prevent HBV reac-
tivation and diminish the risk of severe or fatal HBV
reactivation.79,822012  ERADICATE-B cohort study
HBsAg seropositive rates in the children decreased to 0.9%
2013  Upgraded REVEAL-HBV risk calculator for HCC
2014  C-TEAM cohort study
Population-based nationwide study
20??  HBV eradication
Figure 2 Strategies and achievements for the control of
hepatitis B disease in Taiwan. HBsAg Z hepatitis B surface
antigen; HBV Z hepatitis B virus; HCC Z hepatocellular
carcinoma.Perspectives in Taiwan: Towards HBV
eradication
Although the efficacy of antiviral therapy has dramatically
improved the long term outcomes of CHB, clearance of
HBsAg is only observed in a small portion of Asian patients
with chronic HBV infection. For example, 1 year PEG-IFN
monotherapy led to HBsAg seroconversion in 3e5% of pa-
tients at 6 months of therapy.83e85 Similarly, the HBsAg loss
rates for HBeAg-positive patients treated with ETV or LAM
for 2 years were 5% and 3%, respectively.86 Although HBsAg
loss could be achieved in 11.8% of HBeAg-positive patients
after 7 years of TDF therapy, it only occurred in Caucasian
patients with genotype A or D infection.87 Therefore,
eradication of HBV infection is still a daunting challenge
ahead, especially in Asian patients who acquire the virus
early in life. Recently, several potential strategies for HBV
eradication aimed at viral and host targets responsible for
HBV persistence have been developed.88 Several novel
therapeutic approaches will be briefly introduced. The first
one, Myrcludex-B, a lipopeptide derived from the pre-S1
domain of the HBV envelope protein, which targets the
HBV receptor, the sodium taurocholate co-transporting
polypeptide (NTCP),89 has been shown to efficiently
inhibit HBV entry.90 The second one is zinc-finger nuclease
(ZFN). Through blocking transcription of cccDNA, ZFN can
be used to inhibit viral transcription and replication of duck
HBV.91 In vitro studies also revealed effective cleavage of
viral DNA targets by HBV-specific ZFN within cultured
cells.92 Lucifora et al93 recently reported that IFN-a and
lymphotoxin-b receptor activation upregulated apolipo-
protein B mRNA editing enzyme, catalytic polypeptide 3A
(APOBEC3A) and APOBEC3B cytidine deaminases in HBV
infected cells, resulting in noncytolytic clearance of
cccDNA and preventing HBV reactivation.
Agents targeting host factors to enhance innate and
adaptive immune responses may play an important role in
elimination of HBV infected cells. The toll-like receptor
(TLR) family is an important regulator of innate and adap-
tive immune responses to various pathogens.94 Exogenous
interferon stimulation by TLR agonists may reinstate
endogeneous IFN-a responses and result in innate and
adaptive immune reconstitution.95 GS-9620, a selective oral
TLR7 agonist, could induce prolonged suppression of HBV
DNA in the serum and liver in chronically infected chim-
panzees. Furthermore, serum HBsAg and HBeAg levels, and
numbers of HBV antigen-positive hepatocytes, were
reduced while hepatocyte apoptosis were increased.96Antiviral immunity plays an important role in the control
of HBV infection, and therapeutic vaccines have been
considered as a promising strategy. Martin et al97 developed
a novel adenovirus-based therapeutic vaccine, TG1050,
encoding three HBV antigens or domains, including core,
polymerase, and envelope proteins. They demonstrated
that long-lasting HBV-specific memory CD8 T cells could be
induced by TG1050 in mouse models.97 Although reduction
of HBsAg and HBV DNA levels could be observed in mouse
models, the magnitude of reduction might not be enough to
eradicate persistent HBV or control viral replication in
humans.98 In the future, the new agents in conjunction with
long term NA therapy may lead to the development of
protective immunity against HBV with subsequent eradi-
cation of HBV.88,95
Conclusion
Effective vaccines against HBV infection have been avail-
able for more than three decades, and the effectiveness of
universal hepatitis B vaccination to decrease hepatitis B
carriage and HCC in children and young adults is confirmed
by the long term follow-up survey.12 In addition, HBV fac-
tors affecting liver disease remission or progression have
been elucidated and risk calculator for HBV-related HCC
has been developed and validated from HBV natural history
cohorts from Taiwan. Ample evidence also indicates current
anti-HBV therapies significantly reduce the risk of HBV-
related cirrhosis and HCC (Figure 2). However, CHB still
remains a major global health threat because of the
Control of HBV infection in Taiwan 907existence of 240 million patients with chronic HBV infection
across the world. The recent publication of “Guidelines for
the prevention, care and treatment of persons with chronic
hepatitis B infection” by the World Health Organization
further highlights this important health issue.99 With the
development of more effective measures, the ultimate goal
of a HBV cure can be achieved in the foreseeable future.
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